Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • AUD/USD

    0.6504
    -0.0032 (-0.49%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    81.73
    +0.38 (+0.47%)
     
  • GOLD

    2,213.50
    +0.80 (+0.04%)
     
  • Bitcoin AUD

    108,254.59
    +959.67 (+0.89%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

When Should You Buy Euromoney Institutional Investor PLC (LON:ERM)?

Euromoney Institutional Investor PLC (LON:ERM), is not the largest company out there, but it saw significant share price movement during recent months on the LSE, rising to highs of UK£11.08 and falling to the lows of UK£9.90. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Euromoney Institutional Investor's current trading price of UK£10.50 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Euromoney Institutional Investor’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for Euromoney Institutional Investor

Is Euromoney Institutional Investor still cheap?

Great news for investors – Euromoney Institutional Investor is still trading at a fairly cheap price. My valuation model shows that the intrinsic value for the stock is £13.81, but it is currently trading at UK£10.50 on the share market, meaning that there is still an opportunity to buy now. However, given that Euromoney Institutional Investor’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

What does the future of Euromoney Institutional Investor look like?

earnings-and-revenue-growth
earnings-and-revenue-growth

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With revenues expected to grow by 40% over the next couple of years, the future seems bright for Euromoney Institutional Investor. If the level of expenses is able to be maintained, it looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? Since ERM is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.

ADVERTISEMENT

Are you a potential investor? If you’ve been keeping an eye on ERM for a while, now might be the time to enter the stock. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy ERM. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed investment decision.

Since timing is quite important when it comes to individual stock picking, it's worth taking a look at what those latest analysts forecasts are. At Simply Wall St, we have the analysts estimates which you can view by clicking here.

If you are no longer interested in Euromoney Institutional Investor, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.